Hangzhou, China – The fifth edition of China Valve (Hangzhou) 2019 was held from April 19 to 21, 2019. The conference was honored to have the attendance of the world's top-tier valvular interventional experts, with the aim to drive further development of China's valvular interventional treatment and promote the international exchange and cooperation on interventional treatment of valvular heart diseases. Over 1,000 healthcare professionals and researchers from across the world also attended the conference. MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") presented at the conference its independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow") and VitaFlow® II Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow® II"), which attracted wide attention.
This year's edition added a new session of Global Live Demo that brought together top valvular heart teams worldwide. MicroPort® CardioFlow teamed up with Second Affiliated Hospital, Zhejiang University School of Medicine and Zhongshan Hospital Affiliated to Fudan University respectively to livestream two smooth operations of the second-generation clinical trial of VitaFlow® II. The outstanding post-operative clinical results gave rise to heated discussions between the doctors who performed the operations and the viewers.
During the New Device session on the afternoon of April 21, Prof. Daxin Zhou from Zhongshan Hospital Affiliated to Fudan University spoke of VitaFlow® II. VitaFlow® II inherits the unique motorized handle design of VitaFlow®. It can be completely recaptured before 75% deployment. The reinforced inner and outer shafts still retain flexibility and can be bent 360 degrees. The product also innovatively introduces the integrated sheath to widen the range of the sizes of access artery and effectively reduces the incidence rate of vascular complications. In addition, VitaFlow® II is accompanied with balloon dilation catheter and introducer set to provide the patients suffering severe aortic stenosis and doctors with a comprehensive integrated therapeutic solution. As a result, the safety and efficacy of the procedure are increased.
During the conference, MicroPort® CardioFlow held four Hands on Training - TAVR Simulator Operational Trainings. Prof. Xianbao Liu from Second Affiliated Hospital, Zhejiang University School of Medicine, Prof. Thomas Modine from Centre Hospitalier Régional Universitaire de Lille, Prof. Wenzhi Pan from Zhongshan Hospital Affiliated to Fudan University, and Prof. Longyan Zhang from Wuhan Asia Heart Hospital were respectively invited to introduce the features, application method and outstanding clinical results of the VitaFlow® series products. Meanwhile, MicroPort® CardioFlow also provided the healthcare professionals in attendance with hands-on trainings to operate TAVR simulators, which made them experience the innovative design and excellent performance of the VitaFlow® series products in a more intuitive way. Several top-tier valvular interventional experts from China and overseas visited the booth of MicroPort® CardioFlow during the conference, learned the design rationale of VitaFlow® series products in details, and highly recognized the products' innovative designs and outstanding performance demonstrated in clinical trials. In the future, MicroPort® CardioFlow will roll out a new generation of products and parts and commit to satisfying more unmet clinical needs with integrated valvular interventional treatment solutions.